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Susceptibility to multiple sclerosis (MS) has been linked mainly to the HLA-DRB1 locus,
with the HLA-DR15 haplotype (DRB1*1501-DQA1*0102-DQB1*0602-DRB5*0101) domi-
nating MS risk in Caucasians. Although genes in the HLA-II region, particularly DRB1*1501,
DQA1*0102-DQB1*0602, are in tight linkage disequilibrium, genome-wide-association,
and gene candidate studies identified the DRB1*15:01 allele as the primary risk fac-
tor in MS. Many genetic and immune-functional studies have indicated DRB1*15:01 as
a primary risk factor in MS, while only some functional studies suggested a disease-
modifying role for the DRB5*01 or DQB1*06 alleles. In this respect, the susceptibility
of DRB1*15:01-transgenic (Tg) mice to myelin basic protein- or myelin oligodendro-
cyte glycoprotein-induced MS-like disease is consistent with primary contribution of
DRB1*15:01 to HLA-DR15+ MS. The studies summarized here show that susceptibility
to MS-like disease, induced in HLA-“humanized” mice by myelin oligodendrocytic basic
protein or by the proteolipid protein, one of the most prominent encephalitogenic tar-
get antigens implicated in human MS, is determined by DQB1*06:02, rather than by
the DRB1*15:01 allele. These findings not only offer a rationale for a potential role for
DQB1*06:02 in predisposing susceptibility to MS, but also suggest a more complex
and differential functional role for HLA-DR15 alleles, depending on the primary target
myelin antigen. However, the conflict between these findings in HLA-Tg mice and the
extensive genome-wide-association studies, which could not detect any significant effect
from the DQB1*06:02 allele on MS risk, is rather puzzling. Functional analysis of MS
PBLs for DQB1*06:02-associated anti-myelin autoimmunity may indicate whether or not
DQB1*06:02 is associated with MS pathogenesis.
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INTRODUCTION
Multiple sclerosis (MS), the most common neurological disease
affecting young adults in the Western world, is a CNS demyeli-
nating disease associated with complex pathogenic autoimmunity
against several CNS-myelin target antigens (1). Although the eti-
ology of MS is yet unknown, numerous studies have confirmed
a strong genetic component underlying its etiology. Susceptibility
to MS has been associated with genes within the major histo-
compatibility complex have been recognized for several decades,
particularly with the genes of the HLA-DR2 serotype (DR15
haplotype) (2). The HLA-DR15 association with MS suscepti-
bility was refined later on, using DNA-based typing methods,
to the HLA-DRB1*1501 locus (3). More recent genome-wide-
association studies (GWASs), which identified several MHC genes
and over 100 non-MHC genetic variants/genes associated with MS
Abbreviations: EAE, experimental autoimmune encephalomyelitis; GWASs,
genome-wide-association studies; LD, linkage disequilibrium; MBP, myelin basic
protein; MOBP, myelin-associated oligodendrocytic basic protein; MOG, myelin
oligodendrocyte glycoprotein; MS, multiple sclerosis; PLP, proteolipid protein; Tg,
transgenic mice.
susceptibility (4) have localized the greatest effect on MS risk to
the HLA-DRB1 locus, with the DRB1*15:01 allele within the HLA-
DR15 haplotype bearing the strongest association with MS. How-
ever, the HLA-DR15 haplotype genes (DRB1*15:01, DQA1*01:02,
DQB1*06:02, and DRB5*01:01) are in strong linkage disequilib-
rium (LD). The remarkable LD between these genes makes it
difficult to determine by genetic studies whether the function-
ally relevant effect on MS derives from DRB1*15:01 only, or also
from its neighboring DQA1*01:02-DQB1*06:02 or DRB5*01:01
genes of HLA-DR15 haplotype.
The availability, of “humanized” mice [HLA-transgenic (Tg)
mice] that were genetically manipulated to express either of the
human DRB1*15:01, DQA1*01:02-DQB1*06:02, or DRB5*01:01
molecules, provide a powerful tool to discern the potential con-
tribution of each of these three sets of genes, individually or in
combination (epistasis), to the development of MS.
Most previous genetic and immunological studies suggested
DRB1*15:01 as the disease-predisposing gene in MS (5, 6) are in
agreement with the GWASs, suggesting that greatest risk to MS is
driven by the HLA-DRB1*15:01 allele, while association to MS of
other alleles of DR15 haplotype is only secondary to their LD with
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HLA-DRB1*15:01 allele (4, 7). The HLA-II-Tg mice studies show-
ing that HLA-DRB1*1501-Tg mice are susceptible to myelin basic
protein (MBP)- or myelin oligodendrocyte glycoprotein (MOG)-
induced experimental autoimmune encephalomyelitis (EAE) (8,
9) are also consistent with the primary contribution of DRB1*1501
to MS pathogenesis. However, we recently showed that “human-
ized”mice expressing DQB1*06:02, but not the DRB1*15:01, genes
can develop MS-like disease mediated by autoimmune cells reac-
tive against a CNS protein, myelin oligodendrocytic basic pro-
tein (MOBP) (10), which is also an important target antigen
for the immune attack in MS. These findings were the first to
implicate DQB1*06:02-associated immune cells in the pathogen-
esis of MS, and to suggest that DQB1*06:02 is also a potential
disease-predisposing gene. The DQB1*06:02-associated patho-
genic autoimmunity against MOBP target antigen appeared not
to be a limited case. We found that the pathogenic autoimmunity
against the proteolipid protein (PLP), a highly encephalitogenic
target antigen in MS, is also determined by HLA-DQB1*06:02,
and not by HLA-DRB1*15:01 allele (10, 11).
Here, we review our and others’ studies, which implicate
pathogenic DQB1*06:02-associated autoimmunity in the patho-
genesis of MS and highlight the possibility that DQB1*06:02 is
also an important disease-predisposing allele, rather than just
disease-modifying as previously perceived (10–14).
HLA-DR15 HAPLOTYPE AND MS
Multiple sclerosis is associated with complex pathogenic autoim-
munity directed against CNS components, with several of the
myelin proteins, such as MBP, PLP, MOG, and MOBP, being the
major potential target antigens in MS. The genetics of MS is com-
plex; in recent GWASs, several HLA and over 100 non-HLA genes
have been associated with the disease, with the DRB1*15:01 within
the extended HLA(-DQB1*06:02, -DQA1*01:02, -DRB1*15:01,
-DRB5* 01:01) haplotype (“HLA-DR15” haplotype thereafter)
bearing the strongest association to MS (4, 15, 16). Nevertheless,
extensive LD among these loci, makes it difficult not unequivocally
establish by fine-genetic mapping studies whether the function-
ally relevant effect on MS derives from DRB1*15:01, DQA1*01:02,
DQB1*06:02, or DRB5*01:01 loci of HLA-DR15, their com-
bination, or from their epistatic interactions. Although many
previous genetic studies indicated DRB1*15:01 as the primary
risk factor in MS among the Caucasian populations (5, 17, 18),
studies with unique populations show selective association with
DRB1*15:01 independent of DQB1*06:02 [African–Americans
(19)]. In African–Brazilian MS patients, the association was
with HLA-DQB1*06:02 rather than HLA-DRB1*15:01 (13). More
recent studies showed that individuals with incomplete haplotypes
bearing only HLA-DRB1*15:01 or HLA-DQB1*06:02 were not
predisposed to MS; the HLA-DQA1*01:02, which by itself shows
no primary association with MS, increases the risk of MS when
combined with HLA-DRB1*15:01 in trans, and plays a protective
role in the absence of HLA-DRB1*15:01 (20). This study also sug-
gested that all three HLA-DRB1, HLA-DQA1, and HLA-DQB1
alleles can affect MS susceptibility through epistatic interactions
(20). In addition to HLA-DRB1*15:01, there are other HLA-DRB1
alleles that can also increase MS risk [such as HLA-DRB1*17:03
allele in the Swedish and Canadian MS populations (21)], albeit to
a lesser extent, while other HLA-DRB1 alleles, particularly HLA-
DRB1*14 can abrogate the risk associated with HLA-DRB1*15
when they are inherited together (22), apparently via functional
epistasis. Thus, the effect of the MHC on susceptibility to MS
appears quite complex as it may involve also complex interactions
between alleles of HLA haplotypes through cis or trans functional
epistatic interactions, suggesting the significance of haplotypic
rather than allelic association between HLA and MS. Yet, the
HLA-DR15 haplotype, comprising the DRB1*15:01, DQA1*01:02,
DQB1*06:02, and DRB5*01:01 alleles, is the most prevalent
haplotype (~30%) among MS patients of the Western population.
HLA-DQB1*06:02 ALLELE IN UNIQUE POPULATIONSWITH MS
While most MS genetics studies in North European, Caucasian
populations suggest the HLA-DRB1*15:01 as the genetic risk fac-
tor in MS (5), Spurkland, Thorsby, and Vartdal studied the specific
HLA-DR and DQ alleles of 181 Norwegian MS patients. Patients
who carried DQB1*06:02 or 06:03 without DRB1*15:01 were iden-
tified, but none who were DRB1*15:01 without DQB1*06:02 (23)
were identified. Related observations were made in a relatively
small cohort of Hong Kong Chinese patients with MS. In this spe-
cific Chinese patients, DR15 is expressed without DQB1*06:02 and
DQB1*06:02 without DR15, so that one can ask whether either or
both of the dissociated genes appear to confer an enhanced risk.
It was found that the enhanced risk to MS was associated with
DQB1*06:02 (12). A similar case has been made for MS susceptibil-
ity in Afro-Brazilians, where the frequency of DQB1*06:02 among
patients is higher than for the main DR15 allele in that unique
population, DRB1*15:03 (13). Hence, in African populations that
show greater haplotypic diversity than European and also distinct
patterns of LD, it was possible to separately appraise the relative
contributions of HLA-DR and DQ sequences to susceptibility. A
caveat here is the analysis of HLA-DR and DQ associations con-
ducted in a large cohort of African American MS patients, where
a selective association with HLA-DRB1*15:01 and not with HLA-
DQB1*06:02 was identified (19). Another study in MS patients
from Malaga, Spain, that showed association of HLA-DQB1*06:02
with MS in the absence of DRB1*15:01 (14) is in line with the
findings in the African Brazilians. These studies suggest that HLA
DRB1*15:01 may not be the sole determinant of MS susceptibility.
MYELIN T-CELL EPITOPES IN HLA-Tg MICE
Immunodominant epitopes in MS are also often encephalitogenic
epitopes in relevant susceptible experimental animals [e.g., MBP
89-101 in SJL/J mice (24), PLP 43-64 in Pl/J mice (25), MOG 35-55
in H-2b mice (26, 27), Lewis rats (28) and Rhesus monkeys (29),
and MOBP 65-86 in H-2b mice (30)]. Nevertheless, these animal
models do not fully reflect the immune responses seen in MS. In
this regard, HLA-Tg mice are a more powerful tool for the analysis
of human T-cell responses to myelin epitopes, their association
with particular HLA-restriction elements, and their pathogenic
credentials. Proof of principle that human T-cell responses can
be studied in the “humanized” HLA-Tg mouse model was pro-
vided by the demonstration of T-cell responses to MBP 139-154
in HLA-DR Tg mice (8) and the induction of EAE with MBP 84-
102 in HLA-DR2-transgenic mice, which also express a human
TCR recognizing the MBP epitope (31).
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In the study of Sireci et al., MBP13–33, 139–154, and 87–
106, reported as being presented by different HLA class II alleles,
were tested for their ability to induce HLA restricted proliferative
responses in HLA-DR1 Tg mice (32). Of these, only MBP13–33
induced severe EAE in the HLA-DR1 Tg mice (32); MBP87–106,
which is an immunodominant MBP epitope in MS, induced only
weak responses and very mild EAE (32). A more comprehen-
sive study in HLA-Tg of the HLA-restriction of MBP epitopes
was conducted by Das et al. (33). In their study, the reactivity to
overlapping peptides spanning the MBP molecule by cells isolated
from myelin-primed mice singly transgenic for HLA-DR3, -DQ6,
or -DQ8, or double transgenic for HLA-DR3/DQ6 or -DR3/DQ8,
was investigated, and a strong T-cell response to MBP81-100 was
observed in HLA-DR3/DQ8 Tg mice resulting in severe EAE (33).
Reports on the association of PLP epitopes with specific HLA
alleles in HLA-Tg mice are scarce. PLP175-192 considered as
immunodominant in HLA-DR4 individuals could induce a strong
response accompanied with clinical symptoms of EAE in HLA-
DR4-IE Tg mice (34); T-cell lines to the HLA-DR2 MS-associated
PLP95-116 that were raised from HLA-DR2 Tg mice could induce
neurological impairment upon transfer into these mice (10, 35).
More recently, TCRPLP45–53 Tg mice were generated and were used
to prepare the HLA-A3/TCRPLP45–53 double Tg mice (36). The
most comprehensive studies in HLA-Tg mice have been conducted
to identify the immunodominant epitopes of MOG (37, 38). In the
study of Khare et al. (38), HLA-Tg (-DR2, -DR3, -DR4, -DQ6-601,
-DQ6-604, and -DQ8) mice were immunized with recombinant
MOG (rMOG) and the primed lymph node cells tested for reac-
tivity to overlapping peptides. All six transgenics showed strong
responses to MOG1–20, 31–50, and 61–80, which were shown as
immunodominant epitopes in MS (39). HLA-DR2 Tg mice also
reacted to MOG 91-110, which is immunodominant in the T-cell
response to MOG in rhesus monkeys with MOG-induced EAE
(29); HLA-DR4 Tg mice reacted to MOG31–50 and 91–110 and
the potential relevance of this latter epitope to MS pathogenesis
was confirmed by the study of Forsthuber et al. (37). They showed
that HLA-DR4 Tg mice immunized with rMOG respond predom-
inantly to MOG 97–108 and develop severe EAE (37). Another
example of clinical EAE in HLA-Tg mice is the study reporting
MOG35–55-induced EAE in HLA-DR2 Tg mice (9).
Various examples of TCR transgenics expressing MS patient-
derived TCRs (31, 36, 40), or expressing murine TCR-Tg of
pathogenic T-cells (41, 42) have been described. Several new
observations were made in humanized TCR models, progressing
translational, and understanding of MS T-cell responses beyond
the generic observations that have been made with standard
murine EAE models. The humanized transgenic models provide
information that could not be obtained using assays of patient-
derived cells, e.g., pathogenic credentials of autoimmune response
to myelin epitopes. For many years, studies have defined patterns
of autoimmune anti-myelin T-cell responses of MS patients. Some
myelin epitopes were identified to be more disease specific than
others, and some were more clearly related to disease progres-
sion than others. However, as the responses in MS are assessed
in ex vivo cultures, it has not been possible to attribute func-
tional, pathogenic outcomes to these responses. For this purpose,
HLA-Tg mice genetically manipulated to express TCRs specific to
myelin epitope(s) that develop spontaneous MS-like disease are
instrumental.
Strikingly, none of the reported humanized TCR transgenics
express TCR specific for an HLA-DQ6-restricted myelin epitopes.
Furthermore, and quite surprisingly, extensively reviewing the
literature on studies devoted to defining MS-relevant myelin epi-
topes in humans (MS) revealed that little importance was given to
DQ6-presented epitopes, as the vast majority of studies reported
only DR15-associated epitopes. A similar situation was noticed in
the studies on humanized HLA-Tg mice. Only one group (38, 43)
studied EAE in HLA-DQ6-Tg mice, and analyzed epistatic effects
between DQ6 and DR alleles on PLP-induced EAE, although none
of the DQ and DR alleles in these studies (32, 33, 43, 44) were
of the HLA-DR15 haplotype, the most prevalent haplotype in
MS. Thus, it appears that the HLA-DQ6-associated autoimmune
reactivity against CNS antigens has only been poorly explored,
particularly the autoimmunity associated with DQB1*06:02 mol-
ecule of the HLA-DR15 haplotype. The reasons are not clear, and
are even less understood, as DQ6-associated anti-myelin autoreac-
tivity may also play a role in the pathogenesis of MS, as suggested
from studies in some unique populations (12–14) or from our
study showing that DQB1*06:02, but not DRB1*15:01, deter-
mine disease susceptibility to MOBP or PLP in HLA-Tg mice
(10, 11).
HLA-DQB1*06:02-ASSOCIATED SUSCEPTIBILITY TO MS-LIKE
DISEASE INDUCED BY HUMANMOBP IN HLA-TRANSGENICS
MOBP is a CNS-myelin-specific protein that plays a role
in stabilizing the myelin sheath (45). Northern blot analysis,
in situ hybridization, immunochemistry, and immunoelectron
microscopy (45, 46) indicated that MOBP is expressed exclusively
in CNS white matter, and more particularly throughout com-
pact myelin, predominantly at the major dense lines of myelin
(45). The encephalitogenic potential of MOBP was demonstrated
in H-2b mice with the MOBP65-88 being the encephalitogenic
epitope (30), and in the H-2s (47) mice with MOBP15-36 epi-
tope being the immunodominant and encephalitogenic epitope.
The relevance of the autoimmunity against these encephalitogenic
epitopes to the pathogenesis of MS was investigated by ana-
lyzing the autoreactivity to overlapping human MOBP peptides
by MS patients and healthy control individuals. In two separate
studies (30, 47), analysis of the proliferative response to MOBP
peptides by PBLs from MS patients and controls revealed autore-
activity to MOBP1–23, MOBP15–36, and MOBP65–87 epitopes
in MS patients and controls. Although a significant difference
between MS patients and controls could not be determined, two
of the epitopes that were detected by the PBLs, MOBP15–36
and MOBP65–87, were found encephalitogenic for mice, sug-
gesting the relevance of autoimmunity against MOBP15–36 and
MOBP65–87 epitopes to MS pathogenesis (30, 47). In another
study, Holz et al. (48) showed proliferative response to several
human MOBP epitopes by PBLs from relapsing/remitting MS
patients and controls, with reactivity to MOBP21-39 somewhat
higher in MS patients (48).
We used HLA-Tg mice expressing either the DRB1*15:01 or
DQB1*06:02 heterodimers, as well as (DRB1*15:01×DQB1*06:
02)F1 double Tg mice (10), in order to illuminate the relative
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potential contribution of each of these molecules, or their
co-expression, to MOBP-associated pathogenic autoimmunity
in MS patients with the “HLA-DR15 haplotype.” We showed
(10) that while the HLA-DRB1*15:01 transgenics are refractory
to disease induction, the HLA-DQB1*06:02 Tg mice are sus-
ceptible to EAE induction by hMOBP, through pathogenic T-
cells reactive against MOBP15–36 and MOBP55–77 encephal-
itogenic epitopes. HLA(DRB1*15:01×DQB1*06:02)F1 double
Tg mice were also susceptible to EAE induction by hMOBP,
although the DRB1*15:01/MOBP15–36 reactive T-cells are anti-
inflammatory. The presence of the HLA-DRB1*15:01 gene prod-
uct in the HLA-(DRB1*15:01×DQB1*06:02)F1 double Tg mice
did not impose any immunomodulatory effect. The pathol-
ogy was essentially similar between HLA-DQB1*06:02 and HLA
(DRB1*15:01×DQB1*06:02) F1 double Tg mice, and pathologi-
cal manifestations were highly reminiscent of MS. Both immuno-
genic peptides (MOBP15–36 and MOBP55–77) caused overt clin-
ical EAE associated with perivascular and parenchymal infiltrates,
widespread demyelination, axonal loss, and optic neuritis with a
high degree of demyelination in the optic nerve (10). This study,
which presented a new“humanized”model of MS-like disease pro-
vided the first evidence of pathogenic HLA-DQ-associated anti-
myelin autoimmunity, and further implicated the autoimmunity
against MOBP in the pathogenesis of MS (10).
HLA-DQB1*06:02 DETERMINES SUSCEPTIBILITY TO MS-LIKE
DISEASE INDUCED BY PLP IN HLA-DR15 TRANSGENIC MICE
While our recent study (10) showing that MOBP can induce MS-
like disease in HLA-DQB1*06:02-Tg mice offers a rationale for
the HLA-DQB1*06:02 association with MS, it raised the question
of whether DQ6-autoimmunity against other myelin/neuronal
target antigens/epitopes can be pathogenic and may also play a
role in pathogenesis of MS. PLP autoimmunity has been strongly
implicated in MS. Some functional studies have also attempted
to correlate immune reactivity with MS relapse (49). We there-
fore investigated the pathogenic potential of PLP in HLA-Tg
mice expressing the DRB1*15:01 and DQB1*06:02 gene products
of the HLA-DR15 haplotype. Our results (11) showed that the
DQB1*06:02-associated pathogenic autoimmunity against MOBP
is not a limited case, and that DQB1*06:02-autoimmunity against
other CNS antigens may also play a role in the pathogenesis of
MS. We showed that susceptibility to a “humanized” MS-like dis-
ease induced by highly encephalitogenic protein, PLP, which is
the most abundant CNS protein and one of the most promi-
nent target antigens implicated in human MS, is determined
by HLA-DQB1*06:02, and not by DRB1*15:01. Thus, the HLA-
DRB1*15:01 transgenics were found to be refractory to PLP disease
induction, whereas the HLA-DQB1*06:02 transgenics were sus-
ceptible via T-cells reactive against PLP139-151 and PLP175-194
encephalitogenic epitopes. Although both transgenics react against
these epitopes, the PLP139–151 and PLP175–194-reactive T-cells
are of Th2-type in HLA-DRB1*15:01 transgenics, and patho-
genic Th1/Th17-type cells in the HLA-DQB1*06:02 transgenic
mice. The PLP-induced EAE in HLA-DQB1*06:02 transgenic mice
showed a typical caudo-rostral clinical progression that was asso-
ciated with CNS demyelination, axonal damage, and with optic
neuritis. However, unlike usually observed in PLP-induced disease
or other EAE models in the wild type mice, the CNS pathology
in phPLP175–194-induced EAE in HLA-DQB1*06:02 transgenics
was more pronounced in the brain rather than in the spinal
cord (11). Such a strong involvement of cerebellum and brain-
stem exceeding that of spinal cord, which has been suggested by
Stromnes et al. (50) to be a feature of Th17-driven disease, corre-
sponded to the high Th17 secretion by PLP175–194-primed LNC
derived from DQB1*06:02-Tg mice.
SUMMARY
HLA-DR15-Tg mice are instrumental in investigating the
encephalitogenic potential of myelin/neuronal epitopes relevant
to HLA-DR15+ MS in the context of the genes encoding the
individual molecules comprising the HLA-DR15 haplotype. While
the previously reported susceptibility of DRB1*15:01-Tg mice to
MBP- or MOG-induced EAE is consistent with the primary con-
tribution of DRB1*15:01 to MS pathogenesis, our recent studies
in HLA-Tg mice showed that DQB1*06:02 but not DRB1*15:01
determines pathogenic autoimmunity against PLP as well as
against MOBP (10, 11). These findings provide a rationale, and
mechanisms, for the involvement of HLA-DQB1*06:02-associated
pathogenic autoimmunity in the pathogenesis of MS, thereby,
implicating the HLA-DQB1*06:02 in the genetic susceptibility to
MS. This places MS more firmly in the group of autoimmune dis-
eases in which a functional association is presumed, including type
I diabetes and celiac disease (40, 51). The findings showing that
DQB1*06:02 determines pathogenic autoimmunity against PLP
(11) and MOBP (10) together with previously reported studies
showing that DRB1*15:01 determines pathogenic autoimmunity
against MBP and MOG (8, 9) suggest a more complex and differ-
ential genetic predisposition to HLA-DR15+ MS, depending on
the primary CNS target antigen/epitope against which the patho-
genic autoimmunity is primarily directed (or triggered). It is quite
puzzling, however, that the pathogenic DQB1*06:02-associated
anti-myelin autoimmunity that emerged from functional stud-
ies in HLA-Tg mice is not reflected by the extensive GWASs
in MS, which determined the DRB1*15:01 as the major risk
allele in MS without any significant association of DQB1*06:02
with MS risk. Whether the pathogenic DQB1*06:02-associated
autoimmunity is limited to the reductionist transgenic models of
MS, or whether GWASs could not distinguish the DQA1*01:02-
and DQB1*06:02-related functionally relevant effects on MS risk
from the functional effects driven by DRB1*15:01 allele, due to
strong LD, would require functional studies with PBLs of HLA-
DR15+ MS patients, in particular PBLs reactive against MOBP
and/or PLP.
TAKE HOME MESSAGES
• The susceptibility to MS-like disease induced by MBP or MOG
in HLA-Tg mice is determined by DRB1*15:01, while disease
induced by MOBP or PLP is controlled by DQB1*06:02.
• These findings have important bearing on the candidacy of the
DQB1*06:02 allele as genetic risk factor for MS.
• These findings in transgenic models also suggest a more com-
plex and differential functional role for HLA-DR15 genes in
determining susceptibility to MS, depending on the target
brain-myelin antigen.
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